Table 5.
Effects of adrenergic agents on Nor-1 expression in extra-striatal areas
| Veh | Prazosin | Idazoxan | Hal | Prazosin+Hal | Idazoxan+Hal | |
|---|---|---|---|---|---|---|
| Nor-1 mRNA levels (% of vehicle) | ||||||
| mPFC | 100±11 | 114±7 | 110±5 | 72±3 | 110±14 | 110±17 |
| CC | 100±8 | 110±11 | 109±9 | 81±7 | 129±10# | 88±9 |
| AcSh | 100±4 | 113±11 | 109±16 | 312±29*** | 384±21*** | 452±36***## |
| AcC | 100±10 | 127±14 | 117±7 | 333±29*** | 366±53*** | 304±21*** |
| SNc | 100±17 | 89±29 | 85±6 | 208±29* | 216±24* | 195±19* |
| VTA | 100±14 | 77±22 | 72±19 | 177±15* | 175±8* | 95±8# |
CC, Cingulate cortex ; Hal, haloperidol; mPFC, medial prefrontal cortex ; NAcC, nucleus accumbens core ; NAcS, nucleus accumbens shell ; SNc, substantia nigra pars compacta; VTA, ventral tegmental area ; Veh, vehicle.
Values represent mean±S.E.M. from five animals per group
*
p<0.05,
***
p<0.001 vs. Veh group;
#
p<0.05,
##
p<0.01 vs. haloperidol group.